Adults 60 to 85, any sex, with Dementia Prevention or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Dementia Literacy From Baseline to Month 12Primary· 12 months
The primary outcome will be change in dementia literacy following participation in the study, as measured by the Alzheimer's Disease Knowledge Scale (ADKS). The ADKS is designed to assess knowledge about Alzheimer's Disease (AD) among laypeople, patients, caregivers, and professionals. This self-report questionnaire contains 30 true/false items. The total score is the sum of the scores from the 30 items, which is quantitative and ranges from 0-30, with a higher score indicating better knowledge about AD. To aide interpretation, change in ADKS scores were converted to standardized change scores
Group
Value
95% CI
BHSP Main
0.191
-0.014 – 0.397
Change in Self-efficacy From Baseline to Month 12Secondary· 12 months
Change in self-efficacy following participation in the study, as measured by the General Self-Efficacy Scale (GSE). The GSE measures perceived competence in dealing with a range of stressful or challenging situations. This self-report questionnaire contains 10-items, each rated on a 4-point scale (not true at all, hardly true, moderately true, exactly true). The total score is the sum of the scores for the 10 items, which is quantitative and ranges from 10-40, with a higher score indicating more self-efficacy. To aide interpretation, change in GSE scores were converted to standardized change s
Group
Value
95% CI
BHSP Main
0.157
0.042 – 0.272
To Evaluate Usability of BHProSecondary· 12 months
Based on System Usability Scale (SUS). The SUS is an 11-item questionnaire with 5-point Likert scale. The total raw score ranges from 0-43 with a higher score indicating greater usability and satisfaction with Brain Health Pro.
Group
Value
95% CI
BHSP Main
34
± 6
Number of Chapters Completed on BHProSecondary· 12 months
To evaluate engagement with Brain Health PRO, the number of chapters completed on BHPro was calculated. There is a total of 180 chapters (181 when orientation chapter is included) that are available on BHPro. The program allows participants to view 160 chapters (excluding the orientation chapter) when reaching week 45 (the intended length of the BHPro program). After 45 weeks, the remaining chapters that were still locked will become accessible for users interested in viewing all the program content. The range of chapters that could be completed on Brain Health PRo by participants is 1-181, wi
Group
Value
95% CI
BHSP Main
142
± 60
To Evaluate User Acceptance of BHPro With the Technology Acceptance Model Questionnaire (TAMQ).Secondary· 12 months
Based on Technology Acceptance Model Questionnaire. The TAMQ is a 20-item questionnaire (adapted for BHPro) with 7-point scale. The total score ranges between 0-120, with a higher score indicating greater acceptance and satisfaction with BHPro.
Group
Value
95% CI
BHSP Main
94
± 18
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data is collected from Baseline up to 30 days after study participation has ended. This is approximately 1 year for participants who remained in the study until the end and less time for those who withdrew early. Systematic collection of AEs occurred at the following study visits: Baseline, Month 6, Month 12. Non-systematic AE reporting, spontaneous reporting by participant, was also implemented..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP, or CTU) is a comprehensive and innovative program aimed to develop, implement and evaluate an interactive and compelling online educational Brain Health Support Program (BHSP) intervention, called Brain Health PRO (BHPro), with potential to positively influence dementia literacy, lifestyle risk factors, and scale-up to reach the broader Canadian public; enroll and retain a community-dwelling Platform Trial Cohort (PTC) of individuals at risk of dementia; and support an open platform trial to test a variety of multidomain interventions that might further benefit individuals at risk of dementia.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07364019 — The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia
· NA
· not yet recruiting
NCT05167045 — A Pilot Study for the Brain Health Support Program
· completed
Other recruiting trials for Dementia Prevention
Currently open trials in the same condition.
NCT07424443 — Pilot Study of a Brain Health Program in Senior Centers
· NA
· recruiting
Other Baycrest trials
Trials by the same sponsor.
NCT06933667 — Kimel Family Centre for Brain Health and Wellness
· NA
· recruiting
NCT05508841 — Understanding How Alzheimer's Disease Impacts the Therapeutic Response to Transcranial Direct Current Stimulation
· NA
· recruiting
NCT05509387 — Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheime
· NA
· recruiting
NCT05167045 — A Pilot Study for the Brain Health Support Program
· completed
NCT04966260 — Virtual Reality Therapy to Improve Physical and Psychological Symptoms and Quality of Life for End-of-life Patients on a
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baycrest
Last refreshed: 2 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05347966.